



## **Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting**

CHESHIRE, Conn., Nov 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abstracts will be presented at the 2007 ASH annual meeting that is being held December 8 to 11, 2007 at the Georgia World Congress Center in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The abstracts and presentation information can be accessed at the links provided below.

-- "High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter Hillmen et al.

[http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1\\_5416](http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416)

-- "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.

[http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1\\_5204](http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204)

-- "Disease-Related Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle Meyers et al.

[http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1\\_5438](http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438).

The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

-- "Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy" Dr. Monica Bessler et al.

[http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1\\_5302](http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302).

[ALXN-G]

SOURCE Alexion Pharmaceuticals, Inc.

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX